A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer.

The introduction of novel molecular-targeted agents has revolutionised the management of patients with metastatic renal cell carcinoma (mRCC). However, uncertainties remain over sequential or simultaneous combination therapies.